Cero Therapeutics Holdings, Inc. SEC filings CERO
Cero Therapeutics Holdings, Inc. has 445 filings in SEC EDGAR's recent list, going back to Jul 8, 2021. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 7, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Dec 2, 2025 | — |
| DEF 14A | Proxy statement | Nov 28, 2025 | Dec 19, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 17, 2025 | Nov 14, 2025 |
| DEF 14A | Proxy statement | May 7, 2025 | May 29, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 25, 2025 | Apr 25, 2025 |
| DEFA14A | Additional proxy material | Oct 25, 2024 | — |
| DEF 14A | Proxy statement | Oct 15, 2024 | Nov 4, 2024 |
| PRE 14A | Preliminary proxy statement | Oct 2, 2024 | Oct 2, 2024 |
| DEFA14A | Additional proxy material | Sep 18, 2024 | — |
| DEFA14A | Additional proxy material | Sep 10, 2024 | — |
| DEF 14A | Proxy statement | Aug 26, 2024 | Sep 12, 2024 |
| PRE 14A | Preliminary proxy statement | Aug 16, 2024 | Aug 16, 2024 |
| DEF 14A | Proxy statement | Apr 15, 2024 | Apr 30, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 3, 2024 | Apr 3, 2024 |
| DEFM14A | Proxy statement | Jan 22, 2024 | — |
| DEF 14A | Proxy statement | Dec 14, 2023 | Jan 3, 2024 |
| PRE 14A | Preliminary proxy statement | Nov 27, 2023 | Nov 27, 2023 |
| DEFA14A | Additional proxy material | Jul 3, 2023 | — |
| DEF 14A | Proxy statement | Jun 15, 2023 | Jul 5, 2023 |
| PRE 14A | Preliminary proxy statement | May 19, 2023 | May 19, 2023 |
| DEF 14A | Proxy statement | Nov 21, 2022 | Dec 16, 2022 |
| PRE 14A | Preliminary proxy statement | Nov 4, 2022 | Nov 4, 2022 |
Showing 22 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CERO (OTC), CEROW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1870404
- Former names
- CERO THERAPEUTICS HOLDINGS, INC. (until Oct 7, 2026); PHOENIX BIOTECH ACQUISITION CORP. (until Feb 14, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.